[Studies on metabolism and disposition of sizofiran (SPG), an anti-tumor polysaccharide. II. Effects on hepatic drug-metabolizing enzyme system in rats]

Yakugaku Zasshi. 1990 Feb;110(2):159-62. doi: 10.1248/yakushi1947.110.2_159.
[Article in Japanese]

Abstract

The effect of a single or multiple administration of sizofiran (SPG), an anti-tumor polysaccharide, on a hepatic drug-metabolizing enzyme system was studied in rats. When SPG was given intravenously at a single dose of 0.5 or 10 mg/kg, no alteration was observed in activities of aminopyrine (AP) N-demethylase and aniline hydroxylase, and in cytochrome P-450 (P-450) content in the livers of rats 48 h after dosing. However, only AP demethylase activity decreased by 34% after the administration of 200 mg/kg. Similarly, no change in the hepatic enzyme activities and P-450 content was observed for up to 180 d after a single dose of 10 mg/kg. Subcutaneous treatment of animals with either 10 or 40 mg/kg dose for 3 and 6 months resulted in no alteration in the enzyme activities and P-450 content. These results may indicate that the therapeutically effective dose of SPG has no effect on a hepatic drug-metabolizing enzyme system in rats.

MeSH terms

  • Aminopyrine N-Demethylase / metabolism
  • Aniline Hydroxylase / metabolism
  • Animals
  • Antineoplastic Agents
  • Cytochrome P-450 Enzyme System / metabolism
  • Glycosaminoglycans / pharmacology*
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Liver / enzymology*
  • Male
  • Rats
  • Rats, Inbred Strains
  • Sizofiran / administration & dosage
  • Sizofiran / pharmacology*

Substances

  • Antineoplastic Agents
  • Glycosaminoglycans
  • Sizofiran
  • Cytochrome P-450 Enzyme System
  • Aniline Hydroxylase
  • Aminopyrine N-Demethylase